Methods and compositions for treating various indications by lessening oxidative stress in a patient are provided. A pharmaceutical composition comprises between about 0.001% to about 10.0%, or more specifically between about 0.015% to about 5%, sodium iodide or catalase by weight. The iodine ion or the catalase dissociates hydrogen peroxide into water and molecular oxygen to interrupt biological events that result in negative side effects. The pharmaceutical composition further comprises in some cases a reducing agent or various carrier materials. The pharmaceutical composition is in some cases formulated for a variety of delivery methods.

The present disclosure provides compositions and methods for treating vascular smooth muscle cell proliferation in a subject that does not have a deficiency of ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) resulting in a pathological disease of calcification or ossification by administering an ENPP1 agent or an ENPP3 agent.

The present disclosure relates to stable formulations of tissue-type plasminogen activator (tPA). In particular, the disclosure relates to specific new formulations, methods of preparing them and methods of using them.

The present invention relates to an implantable cell chamber device capable of retaining cells but permitting diffusion of biomolecules. Also disclosed are methods for delivering a therapeutic biomolecule to a subject in need thereof on a continuous or semi-continuous basis, by administering to the subject a cell chamber device comprising cells that secrete the therapeutic biomolecule.

The invention concerns methods for the selective, topical or trans dermal delivery or removal of one or more substances to, or from, respectively, the skin or surface of a human or animal subject, via the topical or transdermal application of a porous, polymeric composition capable of releasing or sorbing (adsorbing and/or absorbing) said substances, wherein said porous polymer is a particulate material, with particles having an average diameter in the range of approximately 0.1 microns to approximately 0.5 centimeters, and having a plurality of pores with an average pore diameter in a range of approximately 50 Angstroms to approximately 40,000 Angstroms.

The present application relates to use of transglutaminases to treat various products, including medical devices such as tissue grafts, tissue matrices or other tissue-derived materials, and synthetics. The transglutaminases can be applied to the medical devices to provide advantages such as adhesion resistance or abrasion resistance.

Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising thermolysin.

The present invention relates to an injectable composition for bone regeneration, comprising 1 cc of 6% (w/v) hydrated collagen, 5000 units of thrombin, 0.5 ml of a mixed solution of lidocaine and epinephrine in which the epinephrine amount is 1:100,000 (v/v) on the basis of lidocaine, and acting by being injected into bone marrow. The composition according to the present invention activates undifferentiated cells in bone marrow and also activates the bone regeneration ability in bone marrow through the activation and differentiation of osteoclasts and osteoblasts, and can be a successful treatment method for medication-related osteonecrosis of the jaws (MRONJ) through a myeloid activation treatment method, uses various growth factors for myeloid activation and myeloid activation factors such as cytokines so as to allow for the development of treatment for the fundamental cause of MRONJ through a myeloid activation treatment method, and enables the complete regeneration of jaw bone conditions with respect to aesthetic and function, and thus can be effectively used in the treatment of various diseases caused by bone remodeling failure.

The present disclosure provides compositions and methods for treating Peripheral Artery Diseases in a subject by administering an ectonucleotide pyrophosphatase phosphodiesterase-1 (ENPP1) agent or an ectonucleotide pyrophosphatase phosphodiesterase-3 (ENPP3).

Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.